Vivo Capital, LLC 13F Holdings · Q2 2026
Vivo Capital, LLC reported 47 securities worth $1.10B in its SEC 13F filing for Q2 2026 (period ended 2026-06-30). Top holdings: TRVI (8.68%), PRAX (8.29%), ERAS (6.90%). Among its top 25 positions this quarter: 1 new, 6 added, 6 trimmed.
| Rank | Ticker | Company | Value | % Portfolio | Shares | Action |
|---|---|---|---|---|---|---|
| 1 | TRVI | Trevi Therapeutics Inc | $95.0M | 8.68% | 5.1M | Hold |
| 2 | PRAX | Praxis Precision Medicines | $90.8M | 8.29% | 271,116 | Trimmed |
| 3 | ERAS | Erasca Inc | $75.6M | 6.90% | 4.1M | Trimmed |
| 4 | AVBP | Arrivent BioPharma Inc | $58.4M | 5.34% | 1.7M | Added |
| 5 | ABVX | Abivax SA - ADR | $55.3M | 5.05% | 414,899 | Added |
| 6 | TNGX | Tango Therapeutics Inc | $43.1M | 3.94% | 1.4M | Trimmed |
| 7 | CRVS | Corvus Pharmaceuticals Inc | $41.9M | 3.83% | 2.8M | Hold |
| 8 | DRUG | Bright Minds Biosciences Inc | $39.1M | 3.57% | 557,172 | Hold |
| 9 | SVA | Sinovac Biotech Ltd. | $38.2M | 3.49% | 5.9M | Hold |
| 10 | TENX | Tenax Therapeutics Inc | $36.4M | 3.32% | 2.5M | Added |
| 11 | ACRS | Aclaris Therapeutics, Inc. | $35.4M | 3.23% | 6.7M | Added |
| 12 | DYN | Dyne Therapeutics Inc | $34.6M | 3.16% | 1.6M | Hold |
| 13 | DNTH | Dianthus Therapeutics Inc | $34.5M | 3.15% | 353,998 | Hold |
| 14 | ANRO | Alto Neuroscience Inc | $31.9M | 2.91% | 1.2M | Added |
| 15 | DBVT | DBV Technologies SA | $30.3M | 2.76% | 1.8M | Trimmed |
| 16 | SABS | SAB Biotherapeutics Inc | $28.5M | 2.60% | 7.3M | Trimmed |
| 17 | MLTX | Moonlake Immunotherapeutics | $27.3M | 2.49% | 1.4M | Added |
| 18 | LBRX | LB Pharmaceuticals Inc | $26.0M | 2.37% | 800,000 | Hold |
| 19 | NERV | Minerva Neurosciences Inc | $24.0M | 2.19% | 4.3M | Hold |
| 20 | DSGN | Design Therapeutics Inc | $23.3M | 2.13% | 1.6M | Hold |
| 21 | ORIC | Oric Pharmaceuticals Inc | $20.0M | 1.83% | 1.8M | Hold |
| 22 | CAMP | CAMP4 Therapeutics Corporation | $18.6M | 1.69% | 4.2M | Hold |
| 23 | FTH | Faeth Therapeutics Inc | $18.1M | 1.65% | 722,020 | Hold |
| 24 | ACHV | Achieve Life Sciences Inc. | $18.0M | 1.64% | 2.8M | New |
| 25 | CMPX | Compass Therapeutics Inc | $17.0M | 1.55% | 7.8M | Trimmed |
Source: SEC Form 13F filings · as of 2026-06-30
Every position in this 13F-HR, with its change from the prior quarter.
13F holdings, latest quarter
SourceSEC EDGAR13F-HR